{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:39:15Z","timestamp":1789886355666,"version":"4.0.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.clinbiochem.2015.04.021","type":"journal-article","created":{"date-parts":[[2015,5,4]],"date-time":"2015-05-04T17:41:08Z","timestamp":1430761268000},"page":"818-822","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Galectin-3 in atrial fibrillation: Simple bystander, player or both?"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9523-9054","authenticated-orcid":false,"given":"Giuseppe","family":"Lippi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Cervellin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Sanchis-Gomar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinbiochem.2015.04.021_bb0005","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1161\/circ.114.4.257","volume":"114","author":"Fuster","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.clinbiochem.2015.04.021_bb0010","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.ijcard.2012.12.093","article-title":"Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century","volume":"167","author":"Ball","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.clinbiochem.2015.04.021_bb0015","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","article-title":"Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study","volume":"129","author":"Chugh","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.clinbiochem.2015.04.021_bb0020","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (atria) study","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.clinbiochem.2015.04.021_bb0025","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1161\/CIRCOUTCOMES.111.962688","article-title":"Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993\u20132007","volume":"5","author":"Piccini","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.clinbiochem.2015.04.021_bb0030","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1161\/CIRCOUTCOMES.110.958165","article-title":"Estimation of total incremental health care costs in patients with atrial fibrillation in the United States","volume":"4","author":"Kim","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.clinbiochem.2015.04.021_bb0035","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/europace\/eur241","article-title":"Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options\u2014a report from the 3rd Atrial Fibrillation Competence NETwork\/European Heart Rhythm Association consensus conference","volume":"14","author":"Kirchhof","year":"2012","journal-title":"Europace"},{"key":"10.1016\/j.clinbiochem.2015.04.021_bb0040","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/CIRCULATIONAHA.111.039677","article-title":"Atrial fibrillation: current knowledge and future directions in epidemiology and genomics","volume":"124","author":"Magnani","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.clinbiochem.2015.04.021_bb0045","doi-asserted-by":"crossref","first-page":"e941","DOI":"10.1161\/CIRCULATIONAHA.112.112920","article-title":"Novel risk factors for atrial fibrillation: useful for risk prediction and clinical decision making?","volume":"125","author":"Rienstra","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.clinbiochem.2015.04.021_bb0050","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jegh.2013.12.003","article-title":"Incidence of acute-onset atrial fibrillation correlates with air temperature. Results of a nine-year survey","volume":"4","author":"Comelli","year":"2014","journal-title":"J Epidemiol Glob Health"},{"key":"10.1016\/j.clinbiochem.2015.04.021_bb0055","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/ijcp.12304","article-title":"Biomarkers in atrial fibrillation: an overview","volume":"68","author":"V\u00edlchez","year":"2014","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.clinbiochem.2015.04.021_bb0060","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3109\/07853890.2014.912835","article-title":"Hypercoagulability, D-dimer and atrial fibrillation: an overview of biological and clinical evidence","volume":"46","author":"Danese","year":"2014","journal-title":"Ann Med"},{"key":"10.1016\/j.clinbiochem.2015.04.021_bb0065","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1515\/cclm-2014-0278","article-title":"Practical experience using galectin-3 in heart failure","volume":"52","author":"McCullough","year":"2014","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.clinbiochem.2015.04.021_bb0070","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cca.2014.10.009","article-title":"Rogier van der Velde A, de Boer RA. Galectin-3 and heart failure: prognosis, prediction & clinical utility","volume":"443","author":"Filipe","year":"2015","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.clinbiochem.2015.04.021_bb0075","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3109\/10408363.2013.863267","article-title":"Risk assessment of post-infarction heart failure. Systematic review on the role of emerging biomarkers","volume":"51","author":"Lippi","year":"2014","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1016\/j.clinbiochem.2015.04.021_bb0080","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.clinbiochem.2014.06.001","article-title":"Measurement of galectin-3 with the ARCHITECT assay: clinical validity and cost-effectiveness in patients with heart failure","volume":"47","author":"Gruson","year":"2014","journal-title":"Clin Biochem"},{"key":"10.1016\/j.clinbiochem.2015.04.021_bb0085","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/HCO.0000000000000027","article-title":"Mechanisms of persistent atrial fibrillation","volume":"29","author":"Jalife","year":"2014","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.clinbiochem.2015.04.021_bb0090","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s11886-014-0518-z","article-title":"Assessment and impact of cardiac fibrosis on atrial fibrillation","volume":"16","author":"Akoum","year":"2014","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.clinbiochem.2015.04.021_bb0095","doi-asserted-by":"crossref","first-page":"577","DOI":"10.5603\/CJ.2013.0157","article-title":"The association between galectin-3 and clinical parameters in patients with first acute myocardial infarction treated with primary percutaneous coronary angioplasty","volume":"20","author":"Szadkowska","year":"2013","journal-title":"Cardiol J"},{"key":"10.1016\/j.clinbiochem.2015.04.021_bb0100","doi-asserted-by":"crossref","first-page":"463","DOI":"10.12659\/MSM.890635","article-title":"Novel fibro-inflammation markers in assessing left atrial remodeling in non-valvular atrial fibrillation","volume":"20","author":"Sonmez","year":"2014","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.clinbiochem.2015.04.021_bb0105","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ahj.2014.02.009","article-title":"Galectin 3 and incident atrial fibrillation in the community","volume":"167","author":"Ho","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.clinbiochem.2015.04.021_bb0110","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijcme.2014.10.003","article-title":"Galectin-3 in patients undergoing ablation of atrial fibrillation","volume":"5","author":"Clementy","year":"2014","journal-title":"IJC Metab Endocrinol"},{"key":"10.1016\/j.clinbiochem.2015.04.021_bb0115","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1161\/CIRCHEARTFAILURE.113.000568","article-title":"Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study","volume":"7","author":"Zakeri","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.clinbiochem.2015.04.021_bb0120","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.amjcard.2014.12.021","article-title":"Effects of persistent atrial fibrillation on serum galectin-3 levels","volume":"115","author":"Gurses","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinbiochem.2015.04.021_bb0195","doi-asserted-by":"crossref","DOI":"10.1111\/jce.12637","article-title":"The association of serum galectin-3 levels with atrial electrical and structural remodeling","author":"Yalcin","year":"2015","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.clinbiochem.2015.04.021_bb0130","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.clinbiochem.2012.04.009","article-title":"Galectins testing: new promises for the diagnosis and risk stratification of chronic diseases?","volume":"45","author":"Gruson","year":"2012","journal-title":"Clin Biochem"},{"key":"10.1016\/j.clinbiochem.2015.04.021_bb0135","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1161\/01.CIR.0000147181.65298.4D","article-title":"Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction","volume":"110","author":"Sharma","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.clinbiochem.2015.04.021_bb0140","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.4049\/jimmunol.180.4.2650","article-title":"Regulation of alternative macrophage activation by galectin-3","volume":"180","author":"MacKinnon","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.clinbiochem.2015.04.021_bb0200","doi-asserted-by":"crossref","first-page":"e95254","DOI":"10.1371\/journal.pone.0095254","article-title":"TAIPAI Study Group Aldosterone induced galectin-3 secretion in vitro and in vivo: from cells to humans","volume":"9","author":"Lin","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clinbiochem.2015.04.021_bb0150","doi-asserted-by":"crossref","first-page":"H404","DOI":"10.1152\/ajpheart.00747.2008","article-title":"N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion\/growth-regulatory lectin","volume":"296","author":"Liu","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.clinbiochem.2015.04.021_bb0155","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.jacc.2012.04.063","article-title":"Inflammation in atrial fibrillation","volume":"60","author":"Guo","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinbiochem.2015.04.021_bb0160","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/ATVBAHA.112.300569","article-title":"Galectin-3 mediates aldosterone-induced vascular fibrosis","volume":"33","author":"Calvier","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.clinbiochem.2015.04.021_bb0165","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/CIRCHEARTFAILURE.112.971168","article-title":"Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis","volume":"6","author":"Yu","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.clinbiochem.2015.04.021_bb0170","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jchf.2014.07.015","article-title":"Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33\/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction","volume":"3","author":"Lax","year":"2015","journal-title":"JACC Heart Fail"},{"issue":"7S","key":"10.1016\/j.clinbiochem.2015.04.021_bb0175","doi-asserted-by":"crossref","first-page":"8B","DOI":"10.1016\/j.amjcard.2015.01.035","article-title":"Soluble ST2-Analytical Considerations","volume":"115","author":"Mueller","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinbiochem.2015.04.021_bb0180","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.clinbiochem.2012.09.014","article-title":"Performance characteristics of the ARCHITECT Galectin-3 assay","volume":"46","author":"La'ulu","year":"2013","journal-title":"Clin Biochem"},{"key":"10.1016\/j.clinbiochem.2015.04.021_bb0185","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1515\/cclm-2013-0942","article-title":"Analytical evaluation of the automated galectin-3 assay on the Abbott ARCHITECT immunoassay instruments","volume":"52","author":"Gaze","year":"2014","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.clinbiochem.2015.04.021_bb0190","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ijcard.2013.11.137","article-title":"Relationship between serum galectin-3 values and demographical or biochemical variables in patients without acute coronary syndrome","volume":"171","author":"Lippi","year":"2014","journal-title":"Int J Cardiol"}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912015001666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912015001666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:46:24Z","timestamp":1757864784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912015001666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0009912015001666"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2015.04.021","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Galectin-3 in atrial fibrillation: Simple bystander, player or both?","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2015.04.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}